Drug Trial Radar · NCT06842992
A Phase II Study to Evaluate NH102 for Depression
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Dec 4, 2024
Primary completion
Jul 30, 2025
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.
Conditions
- Major Depressive Disorder (MDD)
Interventions
NH102Drug
5 mg twice daily over 6 weeks, followed by a 1-week tapering period.
NH102Drug
10 mg twice daily over 6 weeks, followed by a 1-week tapering period.
NH102Drug
15 mg twice daily over 6 weeks, followed by a 1-week tapering period.
Duloxetine Hydrochloride Enteric-coated CapsuleDrug
30 mg twice daily for 6 weeks, followed by a 1-week tapering period.
PlaceboDrug
Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 17 items Hamilton Depression Scales (HAM-D17)Time frame: 6 Weeks
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Anhui Mental Health Center
Hefei, Anhui, China
Beijing Huilongguan Hospital
Beijing, Beijing Municipality, China
Chongqing Mental Health Center
Chongqing, Chongqing Municipality, China
Xiamen Xianyue Hospital
Xiamen, Fujian, China
The Affiliated Brain Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shenzhen Kangning Hospital
Shenzhen, Guangdong, China
Hebei Mental Health Hospital
Baoding, Hebei, China
The Second Affiliated Hospital of Henan Medical University
Xinxiang, Henan, China
Zhumadian Second People's Hospital
Zhumadian, Henan, China
Hunan Second people's Hospital
Changsha, Hunan, China
Suzhou Guangji Hospital
Suzhou, Jiangsu, China
Wuxi Mental Health Center
Wuxi, Jiangsu, China
Nanchang Mental Health Center
Nanchang, Jiangxi, China
Jilin Provincial Neuropsychiatric Hospital
Siping, Jilin, China
Shongdong Mental Health Center
Jinan, Shandong, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Frist Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Xi'an Mental Health Center
Xi’an, Shanxi, China
The Fourth People's Hospital of Chengdu
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Tianjin Anding Hospital
Tianjin, Tianjin Municipality, China
Hangzhou Seventh People's Hospital
Hangzhou, Zhejiang, China
Huzhou Third Municipal Hospital
Huzhou, Zhejiang, China
The Affiliated Kangning Hospital of Ningbo University
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.